Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase 3 ENHANCE-2 trial for COPD
Top-line Phase 3 ENHANCE-1 data expected around the end of 2022
Conference call today at 8:30 a.m. EDT / 1:30 p.m. BST
LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended June 30, 2022, and provides a corporate update.
